Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Restructured by A Reverse Merger

Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321


Part 4 Radient Is Being Restructured by A Reverse Merger


In Part 1 we established from our analysis that Radient has continued to be an ongoing entity since it was temporarily voided in the state of Delaware and the temporary revocation of its voluntary revocation of RXPC stock through its wholly owned subsidiary currently in Good Standing and incorporated in Delaware. AMDL Diagnostics Inc. continues to be managed by Doug MacLellan as its President and Akio Ariura as its Secretary. All assets including distributorship agreements and Dr-70 were placed in AMDL Diagnostics since 2009 and continue to sell Onko-Sure through its distributor Uni-Pharma and manufacturer Pharmagene in Taiwan along with its Sales of Onko-Sure through generated sales from company contacts in India by SRL Limited and Metropolis. These sources of revenues are being used to pay down the accounts payable of Radient according to mac in a 8-K filing.

In Part 2 of our analysis we established that Radient and Provista Diagnostics entered into a 5 year exclusive LSA on November 2, 2010 that allowed Provista Diagnostics Inc. to research, develop and commercialize DR-70 for future products and services. Since 2010 PDI has researched and developed DR-70 in combination with their Breast and Lung Cancer tests. In October 2014 the first product researched, developed, and now commercialized is the "LC Sentinel" Lung Cancer test that began as a collaboration of DR-70 and Provista diagnostics autoantibodies and biomarkers in 2010. It is now being offered by former PDX CEO and current Vice President of Development, William Gartner. Wiliam started his solely owned private company Global Cancer Diagnostics Inc. William is currently the President and CEO. We believe GCDX will become a wholly owned subsidiary or a Division of PDI in the near future since the Lung Cancer Test GCDX is selling is the IP of Provista Diagnostics and Radient/AMDL Diagnostics Inc.called LC Sentinel.

In Part 3 from our analysis we showed the agreement between GCDX and Radient in July 2012 was never consummated. We found it strange that the agreement was between Global Cancer Diagnostics and Radient and not AMDL Diagnostics Inc. as was in the case for the distributorship with Uni-Pharma in 2013 and most other distributor agreements.

In Part 4 we will continue our analysis on the continued relationship between Provista Diagnostics/Global Cancer Diagnostics and Radient/AMDL Diagnostics Inc.and the first collaborated product the "Lung Cancer Test"a/k/a LC Sentinel offered from the LSA that was established in 2010. The 5 year exclusive agreement expires on November 2, 2015. The "LC Test" is and will generate revenue to Radient according to the agreement.



First and foremost before we extend our analysis. We must thank a poster who presented these latest two posts to our Radient forum pertaining to the current Canadian development with the introduction of the collaborated LC Sentinel Lung Cancer Test of Provista Diagnostics and Radient/AMDL Diagnostics Inc. to Canada.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112963168

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112972107


Dr-70 a/k/a Onko-Sure was approved in Canada in 2010. Additionally, the test is approved in Canada for lung cancer detection and lung cancer treatment monitoring.

Chilean Firm CeTeCancer to Evaluate Radient’s Lung Cancer IVD for Clinical Applications

Oct 15, 2009

http://www.genengnews.com/gen-news-highlights/chilean-firm-cetecancer-to-evaluate-radient-39-s-lung-cancer-ivd/65494640/

Onko-Sure Cancer Screening Test Enters India

12 April 2010

http://www.medicaldevice-network.com/news/news81959.html

Radient Pharmaceuticals Provides Domestic and International Target Market Details for Its Onko-Sure(R) IVD Cancer Diagnostic Test

08/26/10

Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today target market details for the domestic and international commercialization of its Onko-Sure(R) in vitro diagnostic (IVD) cancer test.

http://www.bloomberg.com/apps/news?pid=conewsstory&tkr=RPC:US&sid=aLc.Jmv9NfdM


Dr. Afsaneh Motamed-Khorasani consulted and brought Genway, Grifols, Radient, Provista, and Uni-Pharma together. Some of her clients include Health Canada and the FDA. She was employed at Radient and could stillbe a consultant. She has a network of Canadian associations.

Radient Pharmaceuticals Announces Dr. Afsaneh Motamed-Khorasani Joins RPC as Director of Oncology

TUSTIN, CA--(Marketwire - May 10, 2010)

http://www.marketwired.com/press-release/radient-pharmaceuticals-announces-dr-afsaneh-motamed-khorasani-joins-rpc-as-director-nyse-amex-rpc-1257196.htm

Dr. Afsaneh Motamed-Khorasani is a medical and scientific affairs specialist with a strong background in biomedical sciences, clinical trial/research and medical/regulatory writing/submission. She is the president and managing director of Neometrix Consulting Inc., which helps global pharmaceutical and medical device companies with their medical and regulatory writing and submissions as well as medical affairs.

http://exclusive.multibriefs.com/author/dr.-afsaneh-motamed-khorasani

Neometrix Consulting Inc. provides a wide range of scientific and technical consulting services to pharmaceutical and medical device clients. We focus on the development of strategic platforms and processes enabling clients to make highly informed decisions, reduce costs, create value and improve performance.

http://www.neometrixconsulting.com/



CLIENTS WE HAVE WORKED WITH INCLUDE:

US Food and Drug Administration (FDA)

Silver Spring, MD, USA

Health Canada

Ottawa, ON, Canada

US Pharmacopeia (USP)

Rockville, MD, USA

Amgen Inc.

Thousand Oaks, CA, USA

Baxter International

Deerfield, IL, USA

Covidien/eV3

Irvine, CA, USA

American Medical Writer Association (AMWA)

Rockville, MD, USA

American Society of Clinical Oncology (ASCO)

Alexandria, VA, USA

Provista Diagnostics

Phoenix, AZ, USA

Genway Biotech Inc.

San Diego, CA, USA

Grifols Inc.

Los Angeles, CA, USA

Radient Pharmaceuticals Corp.

Tustin, CA, USA

Streffco Consulting Inc.

Denver, CO, USA

Randstad Pharma

Deerfield, IL, USA

AMDL Diagnostics

Tustin, CA, USA

UniPharma Co Ltd.

Taiwan

Neohypercodex Inc.

Toronto, ON, Canada

IIR Inc.

Toronto, ON, Canada

Seneca College

Toronto, ON, Canada

Centennial College

Toronto, ON, Canada

Metrix Group Inc.

Toronto, ON, Canada

Mediresources Inc.

Toronto, ON, Canada

Microbix Biosystems Inc.

Mississauga, ON, Canada

Insception Inc.

Mississauga, ON, Canada

Samuel Lunenfeld Research Institute

Toronto, ON, Canada

University of Toronto

Toronto, ON, Canada

University of British Columbia

Vancouver, BC, Canada

Princess Margaret Hospital

Toronto, ON, Canada

Toronto General Hospital

Toronto, ON, Canada

Mount Sinai Hospital

Toronto, ON, Canada

Vancouver General Hospital

Vancouver, BC, Canada

VGH In vitro Fertilization Lab

Vancouver, BC, Canada



http://www.neometrixconsulting.com/sample-page/


Dr. Afsaneh Motamed-Khorasani

16 years of experience in writing, editing and translation (Farsi-English)

http://www.translatorscafe.com/cafe/member187864.htm

http://www.pezeshkan.org/?p=26588

We believe the GCDX/Bertech PR was a smoke screen. Bertech has not shown news on their web site since 2013 and appears to be dormant. We know from the LSA between Radient and Provista Diagnostics it limits PDX to commercialize Dr-70 tests in the USA market only. So the Canadian company distributorship seems to not fit in the equation.

On January 14, 2015, Bertech Diagnostics Ltd. (an enterprise of "The Bertech Group”) announced the signing of a license agreement with Global Cancer Diagnostics of Tempe, Arizona. This agreement enables Bertech to sell The Lung Cancer Test™ in Canada. With this partnership The Lung Cancer TestTM will continue its rapid expansion for use by current and former smokers. The Lung Cancer Test was introduced to the U.S. marketplace in late 2014.


http://www.bioalberta.com/bertech-diagnostics-ltd


Welcome to Bertech Pharma.
We are dedicated to advancing colorectal cancer diagnostics and treatments.

Bertech Pharma Ltd. is a privately-held biotechnology company founded in 2008 focused on the development of innovative products to advance the diagnosis and treatment of colorectal cancer.

Bertech’s goal is to advance diagnosis, assessment and treatment options for clinicians, which will improve outcomes for patients. Development of our leading edge biomarker assays and our new treatment compounds will increase early detection and improve treatment selection and assessment.

http://bertechpharma.com/



Next we need to clarify opinions that have been recently posted. From our analysis in Part 1,2,3,4 it clearly proves William is selling DR-70 along with Provista Diagnostics's autoantibodies and biomarkers..The proof is from the ROC 97% had on his web site and changed it to 92%. His video states it is 97% for women and 98% for men. The specificity, sensitivity and the ROC for Dr-70 as a stand alone compared to the ROC, Specificity, and sensitivity of Dr-70 and Provista's antibodies and biomarkers are much lower.

Here is a link showing the speciticity and sensitivity for Onko-Sure for the detection of lung cancer. it shows Onko-Sure/Dr-70 with a sensitivity of 78% and specificity of 93%. As a stand alone....

SRL Diagnostics – Onko-Sure, Fibrin and Fibrinogen degradation product estimation, 2013

DR-70 Results as a stand alone from the SRL Diagnostics India and Onko-Sure link.

Sensitivity 78%
Specificity 93%

http://www.west-info.eu/it/analisi-del-sangue-13-tipi-tumore-cancro/2012-02-onkosure-fibrin-fdp-in-cancer-mm-2/

From the link below...

Global Cancer Diagnostics is introducing a blood test for Lung Cancer that is 97% Accurate in the early stages when the disease is most treatable.

http://www.azbio.org/member-directory/global-cancer-diagnostics-inc

From the link below....

The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112694916

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

A comparison from all the links above including the GCDX Video below.....

Men......GCDX Video............ROC 98%
Women... GCDX Video............ROC 97%
2010 LC Sentinel data..........ROC 97%

Men Sensitivity..LC Sentinel final studies.GCDX Video....92%
Women Sensitivity.LC Sentinel final studies GCDX Video...89%
2010 Sensitivity.....LC Sentinel.........................87%
2013 Dr-70 as a stand alone...........................78%

Men Specificity...LC Sentinel final studies.GCDX Video.95%
Women Specificity.LC Sentinel final studies.GCDX Video.95%
2010 Specificity LC Sentinel...........................95%
Dr-70 as a stand alone..............................93%

https://www.youtube.com/watch?v=5uHdcIdV90M


The post below is only half true..The results from above clearly prove that William and GCDX are selling Radient/AMDL Diagnostics Inc. Dr-70 in combination with Provista Diagnostics autoantibodies and biomarkers.Called LC Sentinel....

"GCDx is apparently selling DR-70."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112882683



http://www.marketwired.com/press-release/radient-pharmaceuticals-onko-surer-is-proven-effective-early-detection-lung-cancer-otcqx-rxpc-1535485.htm

The post and statement below states restructuring would wipe out RXPC shares. This is absolutely not true. Actually restructuring would be a benefit to present, and future shareholders. Here are a couple of links to help those that are not aware of restructuring. The restructuring of the equity capital firms agreement of the debt for equity in 2011 was completed before RXPC was temporarily and voluntarily revoked by Mac in April 2014. The equity capital firms own collectively 31 to 34 percent of the 4.5 billion RXPC outstanding shares. The Provista Diagnostic angel investors, a/k/a the creeping take over groups own around 56 to 59 per cent of the 4.5 billion RXPC outstanding shares. The conversions were completed before the RXPC stock stopped trading on July 3, 2014.

"Radient restructuring would wipe out RXPC shares."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112978063

Restructuring

https://en.wikipedia.org/wiki/Restructuring


What Is Corporate Restructuring?

http://www.wisegeek.org/what-is-corporate-restructuring.htm


Here is another post below we would like to clarify and elaborate on.

"There is absolutely no way the SEC would allow this merger to happen in 2015 under the terms of this 2010 LOI."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112979102

"Closing Period: In the event that RPC and PDI desire to move forward, the parties shall proceed in good faith during the following Ninety (90) day period to finalize the definitive documents relating to the Merger and to close the transaction.

The Closing Period shall be extended to the extent necessary to receive necessary approvals from RPC’s shareholders, including sufficient time to clear SEC staff and NYSE-Amex staff comments with regard to a Schedule 14A Proxy Statement. PDI understands that it will be required to provide U.S. GAAP audited financials prior to RPC filing such Proxy Statement and that preparation of such financials and RPC shareholder approval shall be conditions to closing of any definitive merger agreement."


"The Closing Period shall be extended to the extent necessary to receive necessary approvals from RPC’s shareholders, including sufficient time to clear SEC staff."

The part about "necessary approvals from RPC's/RXPC shareholders and the Provista Diagnostics shareholders. This should be approved without hesitation since the majority of the shareholders of RXPC would approve the reverse merger. This would include the 31 to 34% of the equity capital firms positions. The Creeping takeover groups Provista Angel investors)who own 56 to 59 per cent would not object as well. The remaining 10 percent of long shareholders should follow suit..The Provista Diagnostics angel investors and family institutional stockholders would not object to the reverse merger.

The second part of the "Closing Period" section of the 2010 LOI. Concerning the sufficient time to clear in regard to a Schedule 14 A Proxy Statement would not have to be cleared with the NYSE-AMEX staff, because RXPC was listed in the OTC Pink Sheets at the time of the voluntary revocation. Therefore, it would not be as difficult to clear through the OTC Pink Sheets as some would like you to believe.

"sufficient time to clear SEC staff and NYSE-Amex staff comments with regard to a Schedule 14A Proxy Statement."

Even though the LOI expired on December 31, 2010, the wording in the agreement (shall be extended) clearly indicates it is still open for the possibility of a reverse merger.

"The Closing Period shall be extended to the extent necessary to receive necessary approvals from RPC’s shareholders...."

The Schedule 14 A Proxy Statement would be cleared with the SEC Staff in relation to be listed on the OTC Pink Sheets, because Radient restructured their equity to debt agreement with all equity capital firms a/k/a lenders. The revenues obtained from Uni-Pharma licensing fees and royalties and those from the LSA of 2010 between Provista and Radient from the commercializing of the LC Sentinel Lung Cancer Test and from the use of DR-70 in the Provista Diagnostics future sales, and not withstanding the over 1 million dollars of revenue from Provista Diagnostics other services.

Here is more proof that "The Lung Cancer Test" is the LC Sentinel..William had to abandon his federal trademark application it was given non-final action. The reason it was rejected is because it was too generic..William and his attorneys should have known this before applying. It was also declined by one of Radient's past distributors. We will post both trademark attempts..

GCDX..The Lung Cancer Test

https://trademarks.justia.com/860/79/the-lung-cancer-86079607.html

Genway Biotech...Lung Cancer Test

https://trademarks.justia.com/778/16/lung-cancer-test-77816896.html


We will expand more on GCDX and Provista Diagnostics continued partnership with Radient/AMDL Diagnostics Inc. and expand on Uni-Pharma, Pharmagene in Taiwan and SRL Limited and Metropolis Healthcare in India and how these entities are expanding the distribution and sales of Onko-Sure on an international basis in Part 5 of our analysis and hypothesis..

Stay tuned to see how Radient Pharmaceuticals is controlling the Global Cancer Diagnostics market behind the scenes, and what the few remaining shareholders will get as a cash distribution / shares of the new company from the upcoming merger!

http://seekingalpha.com/user/8702411/instablog